Table 2.
Human clinical trials with strategies to enhance CAR T trafficking.
| NCT | Title | Phase | Author(s) | Disease(s) | Approach | Status |
|---|---|---|---|---|---|---|
| NCT04185038 | Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | I | Vitanza et al. | DIPG/recurrent pediatric CNS tumors | Locoregional delivery targeting B7-H3 |
Recruiting |
| NCT03696030 | HER2-CAR T Cells in Treating Patients with Recurrent Brain or Leptomeningeal Metastases | I | Pornow et al. |
CNS metastasis | Intraventricular delivery of HER2 CAR T cells for CNS metastasis from HER2+ tumors. |
Recruiting |
| NCT03638167 | EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors |
I | Gust et al. | EGFR-positive recurrent or refractory pediatric CNS tumors | Locoregional delivery targeting EGFR806 |
Recruiting |
| NCT03283631 | Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM (INTERCEPT) | I | Landi et al. | Recurrent GBM | Intracerebral EGFR-vIII CAR T cells | Terminated. Patient enrollment was halted. |
| NCT04153799 | Study of CXCR5 Modified EGFE Chimeric Antigen Receptor Autologous T cells in EGFR-Positive Patients with Advanced Non-Small Cell Lung Cancer | I | Zhang et al. | Advanced non-small-cell lung cancer | CXCR5 modified CAR T cells targeting EGFR | Recruiting |
| NCT03602157 | Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | I | Grover et al. | Relapsed and recurrent Hodgkin lymphoma and cutaneous T cell lymphoma |
CCR4 modified CAR T cells targeting CD30 | Recruiting |
| NCT05081479 | A Study of N-Acetylcysteine (N-AC) in People Receiving CAR T cell Therapy for Lymphoma | I | Batlevi et al. | B cell lymphoma | Reduce tumor reactive oxygen species to condition lymphoma TME for CD19 CAR T cells | Recruiting |
| NCT04976218 | TGFβR-KO CAR-EGFR T Cells in Previously Treated Advanced EGFR-positive Solid Tumors | I | Han et al. | EGFR-positive solid tumors | CAR T cells resistant to TGFβ receptor |
Recruiting |
| NCT03740256 | Binary Oncolytic Adenovirus in Combination with HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors (VISTA) | I | Wang et al. | Advanced HER2+ solid tumors | Oncolytic adenovirus delivers PDL1 blocking mini antibody to enhance CAR T cell killing | Recruiting |
| NCT04381741 | CD19 CAR-T Expressing IL7 and CCL19 Combined with PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma (CICPD) | I | Qian and Liu et al. | Recurrent or relapsed diffuse large B cell lymphoma |
CAR T cells are potentiated with co-expression of IL-7 and CCL19 to better migrate into the TME and enhanced T cell fitness. This approach is also combined with PD1 blocking antibody. | Recruiting |
| NCT03545815 | Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-Knocked Out Mesothelin-Directed CAR-T Cells in Patients with Mesothelin Positive Multiple Solid Tumors | I | Han et al. | Mesothelin-directed CAR T cells | CAR T cells have PD1 TCR receptor knocked out to enhance their activity |
Recruiting |
| NCT02706405 | JCAR014 and Durvalumab in Treating Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | 1b | Gauthier et al. |
B cell non-Hodgkin lymphoma | PDL1 blocking antibody to improved CD19 CAR T cells |
Terminated due to slow accrual |
| NCT03070327 | BCMA Targeted CAR T Cells with or without Lenalidomide for the Treatment of Multiple Myeloma |
I | Mailankody et al. | Multiple myeloma | Lenalidomide has been shown to inhibit regulatory T cells and activate CD8 T cells | Active, not recruiting |